Non-Alcoholic Steatohepatitis (NASH) - Global Clinical Trials Review, 2022
Summary
GlobalData's clinical trial report, “Non-Alcoholic Steatohepatitis (NASH) - Global Clinical Trials Review, 2022 provides an overview of Non-Alcoholic Steatohepatitis (NASH) Clinical trials scenario. This report provides top line data relating to the clinical trials on Non-Alcoholic Steatohepatitis (NASH). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma - Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months
Reasons to Buy
- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level
- Report Guidance
- GlobalData Clinical Trials Report Coverage
- Clinical Trials by Region
- Table Figure 1: Non-Alcoholic Steatohepatitis (NASH) Therapeutics, Global, Clinical Trials by Region (%), 2022*
- Table Non-Alcoholic Steatohepatitis (NASH) Therapeutics, Global, Clinical Trials by Region, 2022*
- Clinical Trials and Average Enrollment by Country
- Table Figure 2: Non-Alcoholic Steatohepatitis (NASH) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2022*
- Table Non-Alcoholic Steatohepatitis (NASH) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2022*
- Table Figure 3: Non-Alcoholic Steatohepatitis (NASH) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2022*
- Table Non-Alcoholic Steatohepatitis (NASH) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2022*
- Top Five Countries Contributing to Clinical Trials in Asia-Pacific
- Table Figure 4: Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2022*
- Table Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2022*
- Top Five Countries Contributing to Clinical Trials in Europe
- Table Figure 5: Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2022*
- Table Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Europe, Top Five Countries, 2022*
- Top Countries Contributing to Clinical Trials in North America
- Table Figure 6: Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, North America, Top Countries (%), 2022*
- Table Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, North America, Top Countries, 2022*
- Top Five Countries Contributing to Clinical Trials in Middle East and Africa
- Table Figure 7: Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2022*
- Table Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2022*
- Top Five Countries Contributing to Clinical Trials in Central and South America
- Table Figure 8: Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2022*
- Table Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2022*
- Clinical Trials by G7 Countries: Proportion of Non-Alcoholic Steatohepatitis (NASH) to Gastrointestinal Clinical Trials
- Table Figure 9: Proportion of Non-Alcoholic Steatohepatitis (NASH) to Gastrointestinal Clinical Trials, G7 Countries (%), 2022*
- Table Proportion of Non-Alcoholic Steatohepatitis (NASH) to Gastrointestinal Clinical Trials, G7 Countries (%), 2022*
- Clinical Trials by Phase in G7 Countries
- Table Figure 10: Non-Alcoholic Steatohepatitis (NASH) Therapeutics, G7 Countries, Clinical Trials by Phase, 2022*
- Table Non-Alcoholic Steatohepatitis (NASH) Therapeutics, G7 Countries, Clinical Trials by Phase, 2022*
- Clinical Trials in G7 Countries by Trial Status
- Table Figure 11: Non-Alcoholic Steatohepatitis (NASH) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2022*
- Table Non-Alcoholic Steatohepatitis (NASH) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2022*
- Clinical Trials by E7 Countries: Proportion of Non-Alcoholic Steatohepatitis (NASH) to Gastrointestinal Clinical Trials
- Table Figure 12: Proportion of Non-Alcoholic Steatohepatitis (NASH) to Gastrointestinal Clinical Trials, E7 Countries (%), 2022*
- Table Proportion of Non-Alcoholic Steatohepatitis (NASH) to Gastrointestinal Clinical Trials, E7 Countries (%), 2022*
- Clinical Trials by Phase in E7 Countries
- Table Figure 13: Non-Alcoholic Steatohepatitis (NASH) Therapeutics, E7 Countries, Clinical Trials by Phase, 2022*
- Table Non-Alcoholic Steatohepatitis (NASH) Therapeutics, E7 Countries, Clinical Trials by Phase, 2022*
- Clinical Trials in E7 Countries by Trial Status
- Table Figure 14: Non-Alcoholic Steatohepatitis (NASH) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2022*
- Table Non-Alcoholic Steatohepatitis (NASH) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2022*
- Clinical Trials by Phase
- Table Figure 15: Non-Alcoholic Steatohepatitis (NASH) Therapeutics, Global, Clinical Trials by Phase (%), 2022*
- Table Non-Alcoholic Steatohepatitis (NASH) Therapeutics, Global, Clinical Trials by Phase, 2022*
- In Progress Trials by Phase
- Table Figure 16: Non-Alcoholic Steatohepatitis (NASH) Therapeutics, Global, Clinical Trials In Progress by Phase, 2022*
- Table Non-Alcoholic Steatohepatitis (NASH) Therapeutics, Global, Clinical Trials In Progress by Phase 2022*
- Clinical Trials by Trial Status
- Table Figure 17: Non-Alcoholic Steatohepatitis (NASH) Therapeutics, Global, Clinical Trials by Trial Status, 2022*
- Table Non-Alcoholic Steatohepatitis (NASH) Therapeutics, Global, Clinical Trials by Trial Status, 2022*
- Clinical Trials by End Point Status
- Table Figure 18: Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Global, by End Point Status, 2022*
- Table Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Global, by End Point Status, 2022*
- Subjects Recruited Over a Period of Time
- Table Figure 19: Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2017-2021
- Table Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2017- 2021
- Clinical Trials by Sponsor Type
- Table Figure 20: Non-Alcoholic Steatohepatitis (NASH) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2022*
- Table Non-Alcoholic Steatohepatitis (NASH) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2022*
- Prominent Sponsors
- Table Figure 21: Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Global, Key Sponsors, 2022*
- Table Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Global, Key Sponsors, 2022*
- Top Companies Participating in Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials
- Table Figure 22: Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2022*
- Table Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2022*
- Prominent Drugs
- Table Figure 23: Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2022*
- Table Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2022*
- Clinical Trial Profile Snapshots
- Appendix
- Abbreviations
- Definitions
- Research Methodology
- Table Figure 24: GlobalData Methodology
- Secondary Research
- About GlobalData
- Contact Us
- Disclaimer
- Source
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook